Opportunistic Neurologic Infections in Patients with Acquired Immunodeficiency Syndrome (AIDS)

Current Neurology and Neuroscience Reports

Volumn 16, Issue 1, 2016, Pages 1-13

  Albarillo, Fritzie ^a,b,c   O’Keefe, Paul ^d  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^b RESURRECTION MEDICAL CENTER   (United States)

^c Northwest Infectious Disease Consultants SC   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AIDS; CNS infections; HIV; Opportunistic infections

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTICONVULSIVE AGENT; ATOVAQUONE; CIDOFOVIR; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; CYTARABINE; ETHAMBUTOL; ETOPOSIDE; FLUCONAZOLE; FLUCYTOSINE; FOLINIC ACID; FOSCARNET; GANCICLOVIR; ISONIAZID; ITRACONAZOLE; MARAVIROC; METHOTREXATE; PYRAZINAMIDE; PYRIMETHAMINE; PYRIMETHAMINE SULFADIAZINE; RIFAMPICIN; RITUXIMAB; STREPTOMYCIN; TEMOZOLOMIDE; TOPOTECAN; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS PATIENT; BLOOD TOXICITY; BRAIN BIOPSY; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; ENCEPHALITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; NEUROIMAGING; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RADIODIAGNOSIS; REVIEW; SEIZURE; SURVIVAL; TOXOPLASMOSIS; TUBERCULOUS MENINGITIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; CENTRAL NERVOUS SYSTEM INFECTIONS; COMPLICATION; DISEASE COURSE; OPPORTUNISTIC INFECTIONS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CENTRAL NERVOUS SYSTEM INFECTIONS; DISEASE PROGRESSION; HUMANS; OPPORTUNISTIC INFECTIONS;

EID: 84953751230     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-015-0603-8     Document Type: Review

References (91)

1. UNAIDS. World AIDS Day 2014 Report. http://www.unaids.org/en/resources/campaigns/World-AIDS-Day-Report-2014/factsheet. Accessed 11 April 2015. The United Nations (UN) releases an updated report of the AIDS epidemic affecting different regions of the world yearly, creating a worldwide awareness of its impact.
2. Tan IK, Smith B, von Geldern G, et al. HIV-associated opportunistic infections of the CNS. Lancet Neurol. 2012;11:605–17. Tan et al. published a comprehensive review of HIV-associated CNS infections. The article discussed the common infections including the epidemiology, clinical presentation, diagnosis and treatment.
3. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 13 April 2015. The Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America updated the guidelines on prevention and treatment of opportunistic infections in HIV-infected adults and adolescents in 2013 and was made available to the public in early 2014. The guidelines are based on case series, prospective cohorts, randomized controlled trials, and recommendations are rated based on the strength of the evidence.
4. Luft B, Remington J. Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992;15(2):211–22.
5. Bilgrami M, O’Keefe P. Neurologic diseases in HIV-infected patients. Handb Clin Neurol Neurol Asp Syst Dis Part III. 2014;121:1321–44.
6. Jones JL, Dargelas V, Roberts J, et al. Risk factors for Toxoplasma gondii infection in the United States. Clin Infect Dis. 2009;49(6):878–84.
7. Buchacz K, Baker R, Palella Jr F, et al. AIDS-defining opportunistic illnesses in US patients, 1994–2007. AIDS. 2010;24:1549–59.
8. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327(23):1643.
9. Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1993;329(14):995–1000.
10. Cohn JA, McMeeking A, Cohen W, et al. Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Am J Med. 1989;86(5):521–7.
11. Skiest D, Erdman W, Chang W, et al. SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect. 2000;40:274–81.
12. Nogui F, Mattas S, Junior G, et al. Neurotoxoplasmosis diagnosis for HIV-1 patients by real-time PCR of cerebrospinal fluid. Braz J Infect Dis. 2009;13:18.
13. Katlama C, De Wit S, O’Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine- sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis. 1996;22(2):268–75.
14. Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med. 1992;116(1):33–43.
15. Leport C, Raffi F, Matheron S, et al. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am J Med. 1988;84(1):94–100.
16. Flinn IW, Ambinder RF. AIDS primary central nervous system lymphoma. Curr Opin Oncol. 1996;8(5):373.
17. Coté TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer. 1997;73(5):645.
18. Shiels MS, Pfeiffer RM, Hall HI, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980–2007. JAMA. 2011;305:1450–59.
19. Skiest D. Focal neurological disease in patients with acquired immunodeficiency syndrome. Clin Infect Dis. 2002;34(1):103–15.
20. Ciacci JD, Tellez C, VonRoenn J, Levy RM. Lymphoma of the central nervous system in AIDS. Semin Neurol. 1999;19:213–21.
21. Wang C, Snow J, Su D. Lymphoma associated with HIV infection. Mayo Clin Proc 1995;70:665.
22. Gaidano G, Carbone A, Dalla-Favera R. Pathogenesis of AIDS related lymphomas: molecular and histogenetic heterogeneity. Am J Pathol. 1998;152:623–30.
23. Surawicz T, McCarthy B, Kupelian V, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro-Oncology. 1999;1:14–25.
24. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med. 1993;119(11):1093.
25. Maher EA, Fine HA. Primary CNS lymphoma. Semin Oncol. 1999;26(3):346–56.
26. Johnson BA, Fram EK, Johnson PC, Jacobowitz R. The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol. 1997;18(3):563.
27. So U, Beckstead J, Davis R. Primary central nervous system lymphoma in acquired immune deficiency syndrome: a clinical and pathological study. Ann Neurol. 1986;20:566–72.
28. Cingolani A, De Luca A, Larocca LM, et al. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst. 1998;90(5):364.
29. Cinque P, Brytting M, Vago L, et al. Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet. 1993;342(8868):398.
30. Antinori A, Ammassari A, De Luca A, et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology. 1997;48(3):687.
31. Newell ME, Hoy JF, Cooper SG, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004;100:2627–36.
32. Jacomet C, Girard PM, Lebrette MG, et al. Intravenous methotrexate for primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS. 1997;11(14):1725.
33. Ferreri A, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–20. 31 October–6 November 2009.
34. Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061. This is a prospective analysis of 44 patients with PCNSL treated with induction methotrexate, temozolomide, and rituximab achieving 66% complete remission followed by high-dose consolidation with etoposide plus cytarabine without whole brain radiation.
35. O’Neil A, Mikesch K, Fritsch K, et al. Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT. Bone Marrow Transplant Adv Online Publ. 2015. doi:10.1038/bmt.2015.18. This is a very recent article describing 5 HIV-infected patients with PCNSL treated with auto-SCT after induction chemotherapy showing promising results.
36. Lednicky JA, Vilchez RA, Keitel WA, et al. Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2003;17:801–07.
37. Koralnik I, Wiithrich C, Dang X, et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol. 2005;57:576–80.
38. Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199(1):77.
39. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4:59–68.
40. Post MJ, Yiannoutsos C, Simpson D, et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol. 1999;20(10):1896–906.
41. Simona B, Giliola C, Francesca M, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis. 2005;40:738–44.
42. Marzocchetti A, Di Giambenedetto S, et al. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol. 2005;43(8):4175–7.
43. Koralnik IJ, Boden D, Mai VX, et al. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology. 1999;52(2):253.
44. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious disease section. Neurology. 2013;80(15):1430–8. The American Academy of Neurology Neuroinfectious Disease Section created an algorithmic approach in the diagnosis of PML based on clinical, imaging, pathologic, and virologic evidence. Two separate pathways were proposed: histopathologic and clinical. Diagnostic classification includes certain, probable, possible, and not PML.
45. Antinori A, Cingolani A, Lorenzini, et al. Italian Registry Investigative Neuro AIDS Study Group. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol. 2003;9 Suppl 1:47.
46. Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med. 1998;338(19):1345.
47. Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16(13):1791.
48. Royal 3rd W, Dupont B, McGuire D, et al. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol. 2003;9(3):411.
49. Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology. 2009;72(17):1458–64.
50. Martin-Blondel G, Cuzin L, Delobel P, et al. Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management? AIDS. 2009;23(18):2545–6.
51. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525–30.
52. Jarvis J, Harrison T. HIV-associated cryptococcal meningitis. AIDS. 2007;21:2119–29.
53. Fessel WJ. Cryptococcal meningitis after unusual exposures to birds. N Engl J Med. 1993;328:1354–5.
54. Darras-Joly C, Chevret S, Wolff M, et al. Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus. Clin Infect Dis. 1996;23:369–76.
55. Brouwer AE, Rajanuwong A, Chierakul W. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial. Lancet. 2004;363(9423):1764.
56. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000;30(1):47.
57. Boulware DR, Rolfes MA, Rajasingham R, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis. 2014;20(1):45–53.
58. Bicanic T, Harrison T. Cryptococcal meningitis. Br Med Bull. 2004;72(1):99–118.
59. Tanner DC, Weinstein MP, Fedorciw B, et al. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol. 1994;32(7):1680.
60. Asawavichienjinda T, Sitthi-Amorn C, Tanyanont V. Serum cyrptococcal antigen: diagnostic value in the diagnosis of AIDS-related cryptococcal meningitis. J Med Assoc Thai. 1999;82(1):65–71.
61. Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368(14):1291–302. Day et al conducted a randomized, three-group, open-label trial of induction therapy for cryptococcal meningitis in patients with HIV infection. The amphotericin plus flucytosine group was associated with improved survival compared with amphotericin B alone.
62. Jarvis J, Bicanic T, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis. 2014;58(5):736–45.
63. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010;50(3):291.
64. Boulware DR, Meya DB, Muzoora C, et al. COAT Trial Team. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487. This is a controlled trial of 177 HIV-infected patients with cryptococcal meningitis randomized to undergo either earlier ART initiation (1 to 2 weeks after diagnosis) or deferred ART initiation (5 weeks after diagnosis). The study concluded that deferring ART for 5 weeks after the diagnosis of cryptococcal meningitis was associated with significantly improved survival, as compared with initiating ART at 1 to 2 weeks.
65. Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992;166(6):1223.
66. Jabs D, Van Natta M, Holbrook J, et al. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Ophthalmology. 2007;114:780–6.
67. Arribas JR, Storch GA, Clifford DB, Tselis AC. Cytomegalovirus encephalitis. Ann Intern Med. 1996;125(7):577.
68. Zurlo JJ, O’Neil D, Polis MA, et al. Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection. Ann Intern Med. 1993;118(1):12–7.
69. Cinque P, Cleator GM, Weber T, for the European Union Concerted Action on Virus Meningitis and Encephalitis, et al. Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. J Neurovirol. 1998;4:120–32.
70. World Health Organization. Global tuberculosis report 2014. http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1. Accessed 15 April 2015. The WHO publishes an annual report on tuberculosis affecting different regions of the world showing its incidence, mortality rate and relationship to HIV.
71. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15:143–52.
72. Scott C, Kirking HL, Jeffries C, et al. Tuberculosis trends–United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(10):265–9.
73. Shanhar P, Manjunath N, Mohan KK, et al. Rapid diagnosis of tuberculous meningitis by polymerase chain reaction. Lancet. 1991;i:5–7.
74. Jarvis J, Meintjes G, Williams A, et al. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010;10:67.
75. Efsen A, Panteleev A, Grint D et al. TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality. BioMed Res Int 2013; vol. 2013, Article ID 373601, 9 pages.
76. Garg R. Tuberculosis of the central nervous system. Postgrad Med J. 1999;75:133–40.
77. British Medical Research Council. Streptomycin treatment of 49 tuberculous meningitis. BMJ. 1948; I: 582–97.
78. Girgis N, Sultan Y, et al. Tuberculous meningitis, Abbassia Fever Hospital–Naval Medical Research Unit No. 3–Cairo, Egypt, from 1976 to 1996. Am J Trop Med Hyg. 1998;58(1):28–34.
79. Thwaites G, Tinh HT. Tuberculous meningitis: many questions, too few answers. Lancet Neurol. 2005;4:160–70.
80. Hosoglu S, Ayaz C, Geyik MF, et al. Tuberculous meningitis in adults: an eleven-year review. Int J Tuberc Lung Dis. 1998;2(7):553–7.
81. Karstaedt AS, Valtchanova S, Barriere R, Crewe-Brown HH. Tuberculous meningitis in South African urban adults. Q J Med. 1998;91:743–47.
82. Kent SJ, Crowe SM, Yung A, Lucas CR, Mijch AM. Tuberculous meningitis: a 30-year review. Clin Infect Dis. 1993;17:987–94.
83. Thwaites G, Chau T, Mai N, et al. Tuberculous meningitis. J Neurol Neurosurg Psychiatry. 2000;68:289–99.
84. Thwaites GE, Chau TT, Farrar JJ. Improving the bacteriological diagnosis of tuberculous meningitis. J Clin Microbiol. 2004;42(1):378.
85. Kennedy DH, Fallon RJ. Tuberculous meningitis. JAMA. 1979;241(3):264.
86. Patel VB, Theron G, Lenders L, et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study. PLoS Med. 2013;10(10):e1001536. This is a prospective study of 235 South-African patients with a meningeal-like illness utilizing Expert MTB/RIF for the diagnosis of tuberculous meningitis. The study showed that this assay had a sensitivity of 62% and a specificity of 95%. This assay was also found to be more sensitive compared to smear microscopy.
87. Verdon R, Chevret S, Laissy J-P, Wolff M. Tuberculous meningitis in adults: review of 48 cases. Clin Infect Dis. 1996;22:982–8.
88. Kumar R, Kohli N, Thavnani H, et al. Value of CT scan in the diagnosis of meningitis. Indian Pediatr. 1996;33:465–68.
89. Offenbacher H, Fazekas F, Schmidt R, et al. MRI in tuberculous meningoencephalitis: report of four cases and review of the neuroimaging literature. J Neurol. 1991;238(6):340.
90. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741.
91. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)–associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374–83.